Clinical trials: Thyroid Eye Disease (TED)
Graves Ophthalmopathy, Graves Disease
Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study
The goal of this observational study is to prospectively validate the efficacy of an AI multimodal model constructed based on multi - sequence orbital MRI in the diagnosis, activity and severity assessment, and prognosis…
- Conditions
- Graves Ophthalmopathy, Graves Disease, Thyroid Associated Ophthalmopathies
- Trial name
- TED-SCOPE-MR (NCT07716397)
- Testing
- MRI scan，ocular ultrasound
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-1 (NCT07720635)
- Testing
- KHN939
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Thyroid-Related Eye Disease
Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)
This is a pilot study to determine the safety and efficacy of orbital injections of LIPO-102.
- Trial name
- NCT00954057
- Testing
- LIPO-102
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 11 people
- Sponsor
- Neothetics, Inc
Thyroid Eye Disease, TED
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.
- Trial name
- NCT07622108
- Testing
- MHB018A
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease (TED)
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
- Trial name
- NCT06812325
- Testing
- VRDN-003
- Where
- 64 sites in United States, France and 5 more
- Volunteers
- 320 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Associated Ophthalmopathies
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152392
- Testing
- IBI311, Follew-up
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
- Trial name
- REVEAL-2 (NCT06625398)
- Testing
- VRDN-003
- Where
- 60 sites in United States, Germany and 4 more
- Volunteers
- 204 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Associated Ophthalmopathies
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152340
- Testing
- IBI311, Glucocorticoids
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease, TED
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-1 (NCT05987423)
- Testing
- Satralizumab
- Where
- 46 sites in United States, Argentina and 8 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
- Trial name
- NCT07142642
- Testing
- Teprotumumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen
Thyroid Eye Disease (TED)
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
- Trial name
- NCT07211776
- Testing
- ZL-1109 (VRDN-003)
- Where
- 26 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- STRIVE (NCT06384547)
- Testing
- Veligrotug
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 231 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
- Trial name
- TED (NCT05683496)
- Testing
- lonigutamab
- Where
- 11 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- ACELYRIN Inc.
Thyroid Eye Disease
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)
- Trial name
- NCT07155668
- Testing
- VRDN-003, Autoinjector
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease, TED
Psychological Burden of Thyroid Eye Disease
This interview study aims to look in depth at the quality of life of people living with TED and their caregivers, with emphasis on impact on mood, relationships, work/education, and leisure.
- Trial name
- NCT07444190
- Testing
- focus groups and individual interviews as well as filling out questionnaires
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Thomas Jefferson University
Thyroid Eye Disease, TED
Treatment of Chronic Thyroid Eye Disease With MHB018A
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
- Trial name
- NCT07622121
- Testing
- MHB018A injection
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease (TED)
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
- Trial name
- RECLAIM (NCT07404111)
- Testing
- VV-14305
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 135 people
- Sponsor
- Kriya Therapeutics, Inc.
Thyroid Eye Disease (TED), Graves Ophthalmopathy
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical…
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Trial name
- THYROSCOPE-TED (NCT07623993)
- Testing
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- THYROSCOPE INC.
Graves Disease, Graves Disease (Basedow's Disease)
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Graves' disease is an autoimmune condition that causes an overactive thyroid. Some people with Graves' disease develop thyroid eye disease, also called Graves' orbitopathy, which can cause swelling around the eyes, eye…
- Conditions
- Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy
- Trial name
- ATORGO (NCT07883356)
- Testing
- Atorvastatin
- Where
- 7 sites in Sweden
- Volunteers
- 554 people
- Sponsor
- Region Skane
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05517421
- Testing
- Batoclimab
- Where
- 93 sites in United States, Canada and 7 more
- Volunteers
- 114 people
- Sponsor
- Immunovant Sciences GmbH